Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
XTNT Stock Forecast 2026-2027
$0.53
Current Price
$72.84M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to XTNT Price Targets
+126.4%
To High Target of $1.20
+107.5%
To Median Target of $1.10
+88.7%
To Low Target of $1.00
XTNT Price Momentum
-3.6%
1 Week Change
+12.8%
1 Month Change
+6.0%
1 Year Change
-32.1%
Year-to-Date Change
-44.2%
From 52W High of $0.95
+20.5%
From 52W Low of $0.44
📊 TOP ANALYST CALLS
Did XTNT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Xtant Medical is one of their latest high-conviction picks.
Latest XTNT Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, XTNT has a bullish consensus with a median price target of $1.10 (ranging from $1.00 to $1.20). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $0.53, the median forecast implies a 107.5% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Chase Knickerbocker at Craig-Hallum, projecting a 126.4% upside. Conversely, the most conservative target is provided by Chase Knickerbocker at Craig-Hallum, suggesting a 88.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XTNT Analyst Ratings
2
Buy
0
Hold
0
Sell
XTNT Price Target Range
Low
$1.00
Average
$1.10
High
$1.20
Current: $0.53
Latest XTNT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XTNT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 31, 2026 | BTIG | Buy | Maintains | $N/A | |
| Nov 11, 2025 | BTIG | Ryan Zimmerman | Buy | Maintains | $1.50 |
| May 16, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $3.00 |
| Dec 5, 2023 | BTIG | Ryan Zimmerman | Buy | Initiates | $2.00 |
| Jul 11, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $1.20 |
| Apr 26, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $1.00 |
| May 17, 2019 | Maxim Group | Hold | Downgrade | $N/A | |
| Dec 8, 2016 | Maxim Group | Buy | Initiates | $N/A | |
| Nov 30, 2016 | Aegis Capital | Buy | Initiates | $N/A |
Xtant Medical Holdings Inc. (XTNT) Competitors
The following stocks are similar to Xtant Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Xtant Medical Holdings Inc. (XTNT) Financial Data
Xtant Medical Holdings Inc. has a market capitalization of $72.84M with a P/E ratio of 19.3x. The company generates $133.93M in trailing twelve-month revenue with a 3.7% profit margin.
Revenue growth is +2.7% quarter-over-quarter, while maintaining an operating margin of -2.9% and return on equity of +10.6%.
Valuation Metrics
Market Cap
$72.84M
Enterprise Value
$92.50M
P/E Ratio
19.3x
PEG Ratio
-29.0x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
+2.7%
Gross Margin
+54.9%
Operating Margin
-2.9%
Net Margin
+3.7%
EPS Growth
+2.7%
Financial Health
Cash/Price Ratio
+23.0%
Current Ratio
2.7x
Debt/Equity
56.4x
ROE
+10.6%
ROA
+4.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Xtant Medical Holdings Inc. (XTNT) Business Model
About Xtant Medical Holdings Inc.
What They Do
Develops innovative medical devices and implants.
Business Model
Xtant Medical Holdings generates revenue by developing and distributing regenerative medicine products and surgical implants that enhance patient outcomes in orthopedic and neurological surgeries. They primarily serve hospitals, surgical centers, and clinics, providing essential tools for patient care while focusing on complex injuries and recovery processes.
Additional Information
The company specializes in biologics and advanced materials aimed at tissue healing, particularly in the spine and orthopedics market, positioning itself as a significant player in the medical technology sector.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
151
CEO
Mr. Sean E. Browne
Country
United States
IPO Year
2015
Website
xtantmedical.comXtant Medical Holdings Inc. (XTNT) Latest News & Analysis
Latest News
Quick Summary
Xtant Medical Holdings, Inc. (NYSE: XTNT) will release its Q1 financial results for 2026 on May 13, 2026, before the market opens.
Why It Matters
The upcoming financial results from Xtant Medical may influence stock performance, affecting investor sentiment and potential trading strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. has launched Trivium™ Shaped, a new pre-shaped bone graft product aimed at enhancing surgical handling for spinal and orthopedic procedures.
Why It Matters
The launch of Trivium™ Shaped expands Xtant Medical's product line, potentially increasing market share and revenue, which could positively impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant has engaged Dilon's U.S. sales team to promote its HEMOBLAST® Bellows product, targeting a $2.0 billion global market for hemostatic products.
Why It Matters
Xtant's partnership with Dilon's sales team could enhance market penetration for HEMOBLAST ® Bellows, potentially driving revenue growth in the lucrative $2.0 billion hemostatic products market.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. (NYSE: XTNT) announced support for the Threshold of Life Memorial in partnership with the Montana Governor's Office, honoring organ and tissue donors.
Why It Matters
Xtant Medical's partnership for a community initiative enhances its brand image and social responsibility, potentially attracting investors focused on ethical and community-driven companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings, Inc. (XTNT) held its Q4 2025 earnings call, discussing financial performance and strategic outlook. Further details are available in the transcript.
Why It Matters
Xtant Medical's Q4 2025 earnings reveal financial performance, guiding future growth and profitability, influencing stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Xtant Medical Holdings reported 2025 revenue of $133.9 million, up 14% year-over-year, with positive net income and adjusted EBITDA. Total cash reached $17.3 million by year-end.
Why It Matters
Xtant's 14% revenue growth and positive net income signal strong operational performance, enhancing investor confidence. Increased cash reserves indicate financial stability and growth potential.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About XTNT Stock
What is Xtant Medical Holdings Inc.'s (XTNT) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Xtant Medical Holdings Inc. (XTNT) has a median price target of $1.10. The highest price target is $1.20 and the lowest is $1.00.
Is XTNT stock a good investment in 2026?
According to current analyst ratings, XTNT has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XTNT stock?
Wall Street analysts predict XTNT stock could reach $1.10 in the next 12 months. This represents a 107.5% increase from the current price of $0.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Xtant Medical Holdings Inc.'s business model?
Xtant Medical Holdings generates revenue by developing and distributing regenerative medicine products and surgical implants that enhance patient outcomes in orthopedic and neurological surgeries. They primarily serve hospitals, surgical centers, and clinics, providing essential tools for patient care while focusing on complex injuries and recovery processes.
What is the highest forecasted price for XTNT Xtant Medical Holdings Inc.?
The highest price target for XTNT is $1.20 from Chase Knickerbocker at Craig-Hallum, which represents a 126.4% increase from the current price of $0.53.
What is the lowest forecasted price for XTNT Xtant Medical Holdings Inc.?
The lowest price target for XTNT is $1.00 from Chase Knickerbocker at Craig-Hallum, which represents a 88.7% increase from the current price of $0.53.
What is the overall XTNT consensus from analysts for Xtant Medical Holdings Inc.?
The overall analyst consensus for XTNT is bullish. Out of 3 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $1.10.
How accurate are XTNT stock price projections?
Stock price projections, including those for Xtant Medical Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 4:23 AM UTC